China Intelligence

China coverage your competitors don't have

Sleuth connects Chinese programs to the global landscape, translated and validated. We monitor the Chinese-language sources where programs surface first, so you see pipeline updates at disclosure, not once they reach a Western database.

Book a Demo

the china blindspot

China can't be a blind spot

18,000+

Chinese assets and growing — buried in Mandarin-language sources your current tools don't reach. Missing them has implications across your business.

~50%

of ADCs, bispecifics & CAR-T worldwide

You can't assess biopharma landscapes with Western data alone

~50% of all ADCs, bispecifics, and CAR-T programs worldwide come from Chinese sponsors.

2,000+

innovative INDs
/ year

Your next competitor is already in development in China

China accepts over 2,000 innovative IND applications per year. Today's preclinical assets will be tomorrow's competitors.

~2,300

assets in late-stage now

A wave of clinical data is coming; rapid triage will be critical

~2,300 Chinese-origin assets are in late-stage development now. Tracking and positioning around the global standard of care is getting far more complex.

335+

out-licensing deals since 2021

Cross-border deal activity has become a core BD channel

335+ out-licensing deals since 2021. The buyer pool grew from 17 to 84 unique companies in four years.

* According to April 2026 Sleuth analysis.

built for action

China intelligence you can act on

Find Chinese assets earlier

Sleuth sources preclinical assets from the places they get disclosed: company websites, WeChat, conference abstracts, and patent filings. See assets at the point of disclosure — not months later when a legacy database catches up.

Chinese data you can trust

Chinese biopharma data is uniquely hard to validate, with conflicting sources and overstated claims. Sleuth continuously validates the data as new evidence arrives — and with hundreds of China-focused engagements delivered, our analyst team helps your team act with confidence.

Assess complete landscapes

Chinese and Western assets surface side-by-side in every analysis — no fragmented workflows or specialized research tracks for China. Your competitive scans, pipeline maps, and TA landscapes are comprehensive by default.

Coverage

Comprehensive China data coverage

Sleuth translates, structures, and integrates Chinese-language primary sources so they sit alongside your Western data automatically — an equivalent source for every standard category in Western databases, plus sources with no Western equivalent at all.

Regulatory

Chinese regulatory filings and decisions — drug approvals, policy changes, enforcement actions, and safety notices — indexed alongside FDA and EMA data.

Clinical Trials

China's clinical trial registries — full trial records with protocol details, enrollment status, and results.

Patents

Chinese patent filings and grants — targets, mechanisms, assignees, and filing dates — indexed alongside USPTO and EPO coverage.

Academic Research

Chinese repositories and regional conference abstracts, with ~8,000 conferences tracked.

Industry & Deal Intelligence

Chinese pharma trade press — R&D updates, regulatory decisions, M&A, licensing deals, financing, and market filings.

Company Data & WeChat

Direct monitoring of tens of thousands of company websites, plus WeChat announcements, analyst commentary, and KOL posts that never reach the open web.

Drug Pricing

Chinese drug pricing data, including NRDL (National Reimbursement Drug List) updates and provincial pricing information.

News & Social

Chinese-language news, press releases, and industry commentary — including sources inaccessible to most Western platforms.

What teams are saying

"The biggest problem we have with our current provider is the information is not always fully up-to-date, especially when it comes to the Chinese pipeline. Sleuth's China data coverage was a deciding factor for us."

Director, Business Development

Top 25 Pharma

>50%

of the top 25 pharma, including companies like Daiichi Sankyo, are leveraging Sleuth's China intelligence.

Learn about the Chinese Biopharma Landscape

Competitive Landscape

China Biopharma Landscape: 18,000+ Assets, 335 Deals, and the Gaps

The translation gap, not the innovation gap, is the binding constraint. 18,000+ Chinese assets, 335 out-licensing deals since 2021, and ~$18B in disclosed upfronts.

Deal Flow

See what your current tools miss in China

See your landscape with China included